Stalevo is a new drug developed for treating Parkinson's disease which comprises of three other drugs - levodopa, carbidopa and entacapone. Stalevo was developed by Finnish pharmaceutical company Orion and marketed in the USA by drugs giant Novartis. In the USA, Stalevo is used in the treatment of Parkinson's of unknown causes in two scenarios. First, to replace individual dosing of the individual drugs found in Stalevo and second, to provide the benefits of Entacapone to those who are finding the combination of just levodopa and carbidopa to longer be effective. With levodopa being a dopamine precursor, carbidopa acting as a carboxylase inhibitor, and entacapone as a COMT inhibitor, using Stalevo is classed as a combination drug therapy.
Stalevo is ideal for those with Parkinson's which has progressed to a point requiring a clinically validated treatment which utilises three unique biochemical pathways, each working differently to help improve patient outcomes. It makes for a more convenient treatment option than individual dosing of the three constituent drugs found within Stalevo and this also improves patient compliance while reducing risks associated to patients miscalculating how much of each of the three drugs should be taken, something which is already a risk for patients with diminished cognitive function from the effects of their disease.
Stalevo is licensed only in the treatment of patients suffering from Parkinson's disease with it being applicable to be used in both sexes. Always refer to product literature.
Stalevo is a complicated drug due to the presence of three different active medicinal components. To this end, Stalevo is dosed carefully with doses being titrated based on the individual needs of the patient involved as well as their history with the three component drugs found in Stalevo.